Study S002791

A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-and-Multiple-Ascending Subcutaneous Doses of DR10624

ClinicalTrials.gov record

Registration

Registration: NCT05378893
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 153
Start: 2022-06-22
Primary completion: 2024-10-10
Lead sponsor: Zhejiang Doer Biologics Co., Ltd.
Conditions: Healthy, Obesity, Metabolically
Interventions: DRUG:DR10624 for injection; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Number of participants with one or more treatment-emergent adverse event (TEAE), serious adverse event (SAE) and adverse event of special interest (AESI). [baseline through day 29(part 1)or day 106(part 2)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.